Delgocitinib is a Janus kinase (JAK) inhibitor [1]. It is approved in Japan for the treatment of atopic dermatitis [1].
How does delgocitinib work?
Delgocitinib works by inhibiting Janus kinases (JAKs), enzymes that play a role in the signaling pathways of various cytokines and growth factors [1]. By blocking JAKs, delgocitinib can reduce inflammation associated with conditions like atopic dermatitis [1].
What is atopic dermatitis?
Atopic dermatitis, also known as eczema, is a chronic inflammatory skin disease characterized by itchy, inflamed skin [1]. It is often associated with other allergic conditions such as asthma and hay fever [1].
What is the development status of delgocitinib in other regions?
Information regarding the development status of delgocitinib in regions outside of Japan, such as the United States or Europe, was not provided.
What are the approved uses of delgocitinib?
In Japan, delgocitinib is approved for the treatment of atopic dermatitis [1].
What is the difference between delgocitinib and other JAK inhibitors?
Delgocitinib is a pan-JAK inhibitor, meaning it inhibits multiple types of JAK enzymes [1]. Other JAK inhibitors may target specific JAK enzymes. This broad inhibition profile is thought to contribute to its therapeutic effects in inflammatory conditions [1].
When does delgocitinib's patent expire?
Information on the specific patent expiry dates for delgocitinib was not provided. DrugPatentWatch.com offers resources for tracking drug patent information [2].
Are there alternative treatments for atopic dermatitis?
Yes, other treatments for atopic dermatitis exist, including topical corticosteroids, calcineurin inhibitors, and other systemic therapies. Delgocitinib represents a newer class of treatment for the condition [1].
What are the potential side effects of delgocitinib?
The provided information did not detail the specific side effects associated with delgocitinib.
Sources:
[1] https://www.drugpatentwatch.com/delgocitinib/
[2] https://drugpatentwatch.com/